ProBioGen AG, a premier service & technology provider for complex therapeutic glycoproteins, has signed a second clinical immuno-oncology development and manufacturing agreement with Tizona Therapeutics, Inc., a privately held immunology company, harnessing the power of the immune system to develop treatments for cancer.  

Under the terms of the agreement, ProBioGen is developing a stable cell line, followed by process development and GMP clinical manufacturing for Tizona’s lead antibody drug candidate.

“Tizona Therapeutics selected ProBioGen based on its excellent CHO.Right development and manufacturing platform,” said Christine O’Brien, vice president of program management at Tizona Therapeutics. “ProBioGen’s collaborative approach, high standard for delivering quality product and timely execution of our project again make them an ideal partner for Tizona.”

Dr. Volker Sandig, ProBioGen’s chief scientific officer added, “ProBioGen’s and Tizona’s teams work together really well and ProBioGen is committed to delivering a quality product candidate within best-in-class development timelines to support potential clinical trials for Tizona Therapeutics.”